婴幼儿血管瘤循证治疗现状  

Current evidence-based treatment of infantile hemangiomas

作　　者：郑家伟[1] 赵泽亮[1] 陈启铭 ZHENG Jia-wei;ZHAO Ze-liang;CHEN Qi-ming(Department of Oromaxillofacial Head and Neck Oncology,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine/College of Stomatology,Shanghai Jiao Tong University/National Center for Stomatology/National Clinical Research Center for Oral Diseases/Shanghai Key Laboratory of Stomatology.Shanghai 200011,China)

机构地区：[1]上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海200011

出　　处：《中国口腔颌面外科杂志》2022年第1期7-14,共8页China Journal of Oral and Maxillofacial Surgery

基　　金：国家自然科学基金(82071130)。

摘　　要：婴幼儿血管瘤是儿童期最常见的良性肿瘤,目前主张早期予以干预,以减少并发症和对心理发育的负面影响。随着β受体阻滞剂的成功应用,治疗方法发生了革命性变化,治疗效果也随之提高。本文结合文献分析,基于循证医学证据,概述了婴幼儿血管瘤各种治疗方法的适应证、优缺点和选择依据,以期为临床应用提供指导。Infantile hemangioma is the most common benign tumor in childhood.Early intervention is currently advocated so as to minimize complications and negative effects on mental development.With the successful application of variousβ-blockers,the treatment methods have undergone revolutionary changes,and the treatment effect has also been improved.Based on literature review and evidence-based medicine,this article summarized the indications,advantages and disadvantages and selection of various treatment methods for infantile hemangioma,in order to provide guidance for clinical application.

关 键 词：婴幼儿血管瘤 循证治疗 Β受体阻滞剂 

分 类 号：R739.8[医药卫生—肿瘤]